Literature DB >> 26291980

Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs.

Uwe Christians1, Alexander A Vinks, Loralie J Langman, William Clarke, Pierre Wallemacq, Teun van Gelder, Varun Renjen, Pierre Marquet, Eric J Meyer.   

Abstract

The immunosuppressants cyclosporine, tacrolimus, sirolimus, everolimus, and probably also mycophenolic acid require therapeutic drug monitoring (TDM)-guided dosing to ensure that blood concentrations are kept within the target range in transplant patients. Reliable, accurate, and precise test methods are therefore essential to effectively monitor levels and to make proper dose adjustments. Data from proficiency testing programs have shown substantial interlaboratory variability. Only few attempts have been made to study the underlying causes. The aim of this study was to systematically document current practices used for immunosuppressant drug TDM in clinical laboratories and identify methodological and practice differences, which may cause the variability observed among laboratories. Data collection was primarily conducted by a structured Web-based survey. Invitations to participate in the survey were distributed to clinical laboratories providing immunosuppressant drug TDM. Surveys were completed by 76 laboratories in 14 countries. The results of our survey suggest that there are 3 main reasons for interlaboratory variability: (1) lack of standardization of laboratory procedures and workflows starting with sample collection and handling, (2) lack of use of appropriate reference materials (eg, isotope-labeled internal standards for liquid chromatography-tandem mass spectroscopy), and (3) poor compliance with internationally accepted good laboratory practice guidelines (eg, related to quality control, quality assurance, validation, training of personnel). The results of the survey also suggest that interlaboratory variability is a multifactorial problem. Technical-level consensus on laboratory operational procedures, quality systems, and personnel training will be of great importance to improve quality and interlaboratory comparability.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26291980     DOI: 10.1097/FTD.0000000000000205

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  5 in total

1.  Could Salivary Cyclosporine Dosage Replace the Whole Blood Cyclosporine Measurements in Renal Transplant Patients?

Authors:  Samia Aboujaoude; Marwan Masri; Sylvana Rizk; Souleima Chamat; Jad Farha; Zeina Majzoub
Journal:  J Int Soc Prev Community Dent       Date:  2017-05-22

2.  Immunosuppressive Drug Measurement by Liquid Chromatography Coupled to Tandem Mass Spectrometry: Interlaboratory Comparison in the Korean Clinical Laboratories.

Authors:  Hyun-Ki Kim; Hyung-Doo Park; Sang-Guk Lee; Hyojin Chae; Sang Hoon Song; Yong-Wha Lee; Yeo-Min Yun; Sunhyun Ahn; Serim Kim; Sun Min Lee; Soo-Youn Lee; Sail Chun
Journal:  Ann Lab Med       Date:  2021-05-01       Impact factor: 3.464

3.  Multi-center Performance Evaluations of Tacrolimus and Cyclosporine Electrochemiluminescence Immunoassays in the Asia-Pacific Region.

Authors:  Xuzhen Qin; Jianzhong Rui; Yong Xia; Hong Mu; Sang Hoon Song; Raja Elina Raja Aziddin; Gabrielle Miles; Yuli Sun; Sail Chun
Journal:  Ann Lab Med       Date:  2018-03       Impact factor: 3.464

4.  Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities.

Authors:  Ron J Keizer; Rob Ter Heine; Adam Frymoyer; Lawrence J Lesko; Ranvir Mangat; Srijib Goswami
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-10-16

5.  Development and Validation of the New Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Unbound Tacrolimus in the Plasma Ultrafiltrate of Transplant Recipients.

Authors:  Magdalena Bodnar-Broniarczyk; Karola Warzyszyńska; Katarzyna Czerwińska; Dorota Marszałek; Natalia Dziewa; Maciej Kosieradzki; Tomasz Pawiński
Journal:  Pharmaceutics       Date:  2022-03-12       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.